

SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-844-305-2331. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization can be delayed.

Drug Requested: Benlysta[®] (belimumab) Intravenous Infusion (J0490) (Medical)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

- Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

Dosage & Administration: Intravenous administration in adults and pediatric patients ≥ 5 years of age with SLE or Lupus Nephritis –10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Reconstitute, dilute, and administer as an intravenous infusion over a period of 1 hour.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

(Continued on next page)

❑ Diagnosis: Active Systemic Lupus Erythematosus (SLE) in patients who are receiving standard therapy

Initial Authorization: 12 months

- ❑ Prescribed by or in consultation with a Rheumatologist
- ❑ Member is 5 years of age or older with a diagnosis of active, autoantibody-positive SLE confirmed by **ONE** of the following (**submit lab results**):
 - ❑ anti-nuclear antibody (ANA) titer \geq 1:80
 - ❑ anti-double stranded DNA (anti-dsDNA) \geq 30 IU/mL
- ❑ Member's SLE activity has been confirmed by **ONE** of the following (**submit results**):
 - ❑ Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of 6-12
 - ❑ \geq 2 British Isles Lupus Assessment Group (BILAG) B organ domain scores
- ❑ Member has tried **three (3)** of the following and is established on **TWO** of the following therapies taken for the last 90 days (**please submit chart notes documenting therapy trials with insufficient disease control**):

<input type="checkbox"/> mycophenolate	<input type="checkbox"/> hydroxychloroquine	<input type="checkbox"/> azathioprine
<input type="checkbox"/> cyclophosphamide	<input type="checkbox"/> methotrexate	<input type="checkbox"/> cyclosporine
<input type="checkbox"/> corticosteroids	<input type="checkbox"/> Other: _____	

- ❑ Member does **NOT** have any of the following limitations to therapy: severe active central nervous system lupus, current or previous diagnosis of progressive multifocal leukoencephalopathy (PML), or concurrent use with other biologics

❑ Diagnosis: Active Systemic Lupus Erythematosus (SLE) in patients who are receiving standard therapy

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ All initial authorization criteria continues to be met
- ❑ Member's response to therapy has been confirmed by **ONE** of the following (**submit results**):
 - ❑ Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score has improved by and/or maintained at a level that is \geq 4 points below baseline score
 - ❑ No new BILAG-A organ domain score OR 2 new BILAG-B organ domain scores
- ❑ Member has an absence of intolerable side effects such as serious infections, signs or symptoms of progressive multifocal leukoencephalopathy (PML), malignancy, severe hypersensitivity reactions/anaphylaxis, or serious infusion reactions

(Continued on next page)

Diagnosis: Active Lupus Nephritis (LN) in patients who are receiving standard therapy

Initial Authorization: 12 months

- Prescribed by or in consultation with a Nephrologist or Rheumatologist
- Member is 5 years of age or older with a diagnosis of active lupus nephritis Class III, IV, or V as confirmed by renal biopsy
- Member's diagnosis of active, autoantibody-positive SLE was confirmed by **ONE** of the following (**submit lab results for documentation**):
 - anti-nuclear antibody (ANA) titer \geq 1:80
 - anti-double stranded DNA (anti-dsDNA) \geq 30 IU/mL
- Member has active renal disease and has received standard therapy for the last 90 days with **ONE** of the following (**chart notes documenting established therapy must be submitted**):
 - mycophenolate
 - calcineurin inhibitor (i.e., cyclosporine, tacrolimus)
 - cyclophosphamide
- Provider must obtain a baseline measurement of **ONE** of the following collected within the last 30 days (**submit lab results**):
 - urine protein:creatinine ratio (uPCR)
 - urine protein
- Member does **NOT** have any of the following limitations to therapy: severe active central nervous system lupus, current or previous diagnosis of progressive multifocal leukoencephalopathy (PML), or concurrent use with other biologics

Diagnosis: Active Lupus Nephritis (LN) in patients who are receiving standard therapy

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- All initial authorization criteria continues to be met
- Member has had improvement from baseline and/or stabilization since last approval of **ONE** of the following (**submit current labs collected within the last 30 days**):
 - urine protein:creatinine ratio (uPCR)
 - urine protein
- Member has an absence of intolerable side effects such as serious infections, signs or symptoms of progressive multifocal leukoencephalopathy (PML), malignancy, severe hypersensitivity reactions/anaphylaxis, or serious infusion reactions

(Continued on next page)

Medication being provided by (check applicable box below):

- Location/site of drug administration: _____
NPI or DEA # of administering location: _____

OR

- Specialty Pharmacy

For urgent reviews: Practitioner should call Sentara Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy , not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****